ERBB2 and breast cancer: The study subjects were a total of 4340 BC diabetic women, of whom 1,992 were ER+/HER2−, 324 were ER+/HER2+, 1446 were TNBC, and 578 HER2 were overexpressing (ER-/PR-/HER2+).